

David V Sheehan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4846255/publications.pdf>

Version: 2024-02-01

145
papers

13,680
citations

47006

47
h-index

20961

115
g-index

148
all docs

148
docs citations

148
times ranked

12098
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale. <i>International Journal of Methods in Psychiatric Research</i> , 2021, 30, e1849.	2.1	1
2	Cross-Validation of the Arabic Mini International Neuropsychiatric Interview, Module K, for Diagnosis of Schizophrenia and the Arabic Positive and Negative Syndrome Scale. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2020, 42, 139-149.	1.2	1
3	Pilot Mental Health Survey, Nepal: Lessons Learned for Survey Design and Instrumentation. <i>Innovations in Clinical Neuroscience</i> , 2020, 17, 17-23.	0.1	0
4	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020, 17, 30-40.	0.1	6
5	Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials. <i>Innovations in Clinical Neuroscience</i> , 2018, 15, 22-29.	0.1	5
6	Restoring function in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2017, 215, 299-313.	4.1	108
7	The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. <i>Brain and Behavior</i> , 2017, 7, e00622.	2.2	25
8	Content validity of the Sheehan Irritability Scale in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2016, 31, 110-117.	1.7	3
9	Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. <i>Human Psychopharmacology</i> , 2016, 31, 53-63.	1.5	20
10	Brexipiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. <i>Journal of Affective Disorders</i> , 2016, 204, 40-47.	4.1	13
11	A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. <i>Eating and Weight Disorders</i> , 2016, 21, 353-364.	2.5	243
12	Importance of Restoring Function in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e908-e908.	2.2	3
13	Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1080-1086.	2.2	6
14	Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1687-1694.	2.2	20
15	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , 2016, 13, 20-31.	0.1	11
16	The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder. <i>primary care companion for CNS disorders</i> , The, 2015, 17, .	0.6	31
17	A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 47-56.	1.4	76
18	A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone Monotherapy in Bipolar Disorder With Co-Occurring Lifetime Panic or Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 77-84.	2.2	23

#	ARTICLE	IF	CITATIONS
19	Rating Scales and Diagnostic Schemata. , 2014, , 1-3.		0
20	Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STs). Innovations in Clinical Neuroscience, 2014, 11, 141-63.	0.1	5
21	The complexity of assessing overall severity of suicidality: a case study. Innovations in Clinical Neuroscience, 2014, 11, 164-71.	0.1	1
22	Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C-SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 172-8.	0.1	4
23	Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case study. Innovations in Clinical Neuroscience, 2014, 11, 179-81.	0.1	1
24	Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 182-90.	0.1	14
25	How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study. Innovations in Clinical Neuroscience, 2014, 11, 191-3.	0.1	0
26	Comparative Validation of the S-STs, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories. Innovations in Clinical Neuroscience, 2014, 11, 32-46.	0.1	15
27	Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis. Innovations in Clinical Neuroscience, 2014, 11, 47-53.	0.1	11
28	Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical Review. Innovations in Clinical Neuroscience, 2014, 11, 54-65.	0.1	5
29	The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?. Innovations in Clinical Neuroscience, 2014, 11, 66-80.	0.1	53
30	Status Update on the Sheehan-Suicidality Tracking Scale (S-STs) 2014. Innovations in Clinical Neuroscience, 2014, 11, 93-140.	0.1	15
31	Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. European Psychiatry, 2013, 28, 190-196.	0.2	4
32	Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study. Journal of Affective Disorders, 2013, 151, 906-913.	4.1	12
33	Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. Journal of Affective Disorders, 2013, 145, 83-94.	4.1	39
34	Sheehan Suicidality Tracking Scale (S-STs): Reliability, convergent and discriminative validity in young Italian adults. Comprehensive Psychiatry, 2013, 54, 842-849.	3.1	15
35	Relationship between major depressive disorder and associated painful physical symptoms. International Clinical Psychopharmacology, 2013, 28, 330-338.	1.7	14
36	Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. <i>International Clinical Psychopharmacology</i> , 2012, 27, 239-248.	1.7	6
38	Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. <i>European Neuropsychopharmacology</i> , 2012, 22, 858-866.	0.7	46
39	Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. <i>European Neuropsychopharmacology</i> , 2012, 22, 847-857.	0.7	63
40	Generalized anxiety disorder. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 343-362.	1.8	20
41	Humanistic and economic burden of generalized anxiety disorder in North America and Europe. <i>Journal of Affective Disorders</i> , 2012, 140, 103-112.	4.1	117
42	Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 211-221.	1.2	88
43	Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. <i>International Clinical Psychopharmacology</i> , 2011, 26, 75-83.	1.7	92
44	Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. <i>Human Psychopharmacology</i> , 2011, 26, 242-251.	1.5	11
45	Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 914-928.	2.2	70
46	Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees. <i>Annals of Clinical Psychiatry</i> , 2011, 23, 285-96.	0.6	6
47	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e1-e21.	2.2	99
48	Reliability and Validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). <i>Journal of Clinical Psychiatry</i> , 2010, 71, 313-326.	2.2	1,140
49	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1040-1046.	2.2	57
50	Adequacy of Pharmacotherapy Among Medicaid-Enrolled Patients Newly Diagnosed with Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2009, 14, 695-703.	1.2	5
51	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. <i>Journal of Affective Disorders</i> , 2009, 115, 376-385.	4.1	59
52	Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1147-1158.	2.8	38
53	Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. <i>International Clinical Psychopharmacology</i> , 2009, 24, 61-86.	1.7	12
54	An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009, 24, 43-60.	1.7	32

#	ARTICLE	IF	CITATIONS
55	Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 222-230.	1.4	64
56	Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. <i>Psychiatry</i> , 2009, 6, 20-33.	0.3	11
57	The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. <i>Psychopharmacology Bulletin</i> , 2009, 42, 5-22.	0.0	45
58	The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. <i>Current Medical Research and Opinion</i> , 2008, 24, 2457-2466.	1.9	20
59	Differences in Medication Adherence and Healthcare Resource Utilization Patterns. <i>CNS Drugs</i> , 2008, 22, 963-973.	5.9	82
60	Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine. <i>Neuropsychopharmacology</i> , 2008, 33, 3201-3212.	5.4	55
61	Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. <i>International Clinical Psychopharmacology</i> , 2008, 23, 70-83.	1.7	319
62	Perceived stress in anxiety disorders and the general population: A study of the Sheehan stress vulnerability scale. <i>Psychiatry Research</i> , 2007, 151, 249-254.	3.3	27
63	Current approaches to the pharmacologic treatment of anxiety disorders. <i>Psychopharmacology Bulletin</i> , 2007, 40, 98-109.	0.0	20
64	The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. <i>Psychopharmacology Bulletin</i> , 2007, 40, 63-81.	0.0	13
65	An open-label study of tiagabine in panic disorder. <i>Psychopharmacology Bulletin</i> , 2007, 40, 32-40.	0.0	10
66	Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy. <i>Neuropsychopharmacology</i> , 2005, 30, 445-460.	5.4	120
67	Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 34-40.	2.2	66
68	Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 34-40.	2.2	51
69	Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. <i>American Journal of Managed Care</i> , 2005, 11, S354-61.	1.1	12
70	Evaluating the Economic Consequences of Early Antidepressant Treatment Discontinuation. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 544-548.	1.4	22
71	A 37-year-old Woman With Treatment-resistant Panic Disorder - or Is it Bipolar Anxiety?. <i>Psychiatric Annals</i> , 2004, 34, 904-910.	0.1	0
72	Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2003, 160, 749-756.	7.2	185

#	ARTICLE	IF	CITATIONS
73	The Tourette's Disorder Scale (TODS). Assessment, 2003, 10, 273-287.	3.1	71
74	Paroxetine treatment of generalized anxiety disorder. Psychopharmacology Bulletin, 2003, 37 Suppl 1, 64-75.	0.0	5
75	Improved tolerability and increased length of therapy. Managed Care, 2003, 12, 23-5.	0.3	0
76	Effect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2002, 287, 1807.	7.4	417
77	Generalized anxiety disorder: comorbidity, comparative biology and treatment. International Journal of Neuropsychopharmacology, 2002, 5, 315-325.	2.1	102
78	Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research, 2002, 36, 209-217.	3.1	61
79	Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamine. Depression and Anxiety, 2002, 16, 89-92.	4.1	73
80	Nicotinic acetylcholine receptors as targets for antidepressants. Molecular Psychiatry, 2002, 7, 525-535.	7.9	261
81	Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment. Managed Care Quarterly, 2002, 10, 21-31.	0.2	0
82	SOCIAL ANXIETY DISORDER. Medical Clinics of North America, 2001, 85, 711-733.	2.5	15
83	Multicenter, Double-Blind, Placebo-Controlled Study of Mecamylamine Monotherapy for Tourette's Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 1103-1110.	0.5	94
84	Family Impact of Tourette's Syndrome. Journal of Child and Family Studies, 2001, 10, 477-483.	1.3	32
85	No: Efforts to relieve human suffering deserve rewards. Western Journal of Medicine, 2001, 175, 365-365.	0.3	0
86	Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety Disorder. American Journal of Psychiatry, 2000, 157, 968-974.	7.2	222
87	Physician Substance Use by Medical Specialty. Journal of Addictive Diseases, 1999, 18, 23-37.	1.3	138
88	Diagnostic Errors of Primary Care Screens for Depression and Panic Disorder. International Journal of Psychiatry in Medicine, 1999, 29, 1-11.	1.8	24
89	A diagnostic aid for detecting (DSM-IV) mental disorders in primary care. General Hospital Psychiatry, 1998, 20, 1-11.	2.4	23
90	DSM-IV-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. European Psychiatry, 1998, 13, 26-34.	0.2	221

#	ARTICLE	IF	CITATIONS
91	Mental Disorders and Disability Among Patients in a Primary Care Group Practice. <i>American Journal of Psychiatry</i> , 1997, 154, 1734-1740.	7.2	354
92	Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale. <i>International Journal of Psychiatry in Medicine</i> , 1997, 27, 93-105.	1.8	845
93	False positive results: a challenge for psychiatric screening in primary care. <i>American Journal of Psychiatry</i> , 1997, 154, 1462-1464.	7.2	34
94	The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. <i>European Psychiatry</i> , 1997, 12, 224-231.	0.2	2,824
95	The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. <i>European Psychiatry</i> , 1997, 12, 232-241.	0.2	1,682
96	Suicidal ideation in primary care. <i>Journal of General Internal Medicine</i> , 1996, 11, 447-453.	2.6	92
97	Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. <i>Anxiety</i> , 1996, 2, 40-46.	0.4	2
98	Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO ₂ in agoraphobic environments. <i>Anxiety</i> , 1994, 1, 275-277.	0.4	2
99	The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 1-11.	4.5	112
100	Resident physician substance use, by specialty. <i>American Journal of Psychiatry</i> , 1992, 149, 1348-1354.	7.2	104
101	Relations among Stressors, Strains, and Substance Use among Resident Physicians. <i>Substance Use and Misuse</i> , 1992, 27, 979-994.	0.6	19
102	Perspectives: Substance Use Among Senior Medical Students: A Survey of 23 Medical Schools. <i>Journal of Addictions Nursing</i> , 1992, 4, 72-79.	0.4	1
103	Prevalence of Substance Use Among U.S. Physicians. <i>Obstetrical and Gynecological Survey</i> , 1992, 47, 771-773.	0.4	5
104	Behavioral Consequences of Job-Related Stress among Resident Physicians: The Mediating Role of Psychological Strain. <i>Psychological Reports</i> , 1991, 69, 339-349.	1.7	21
105	Snorting Benzodiazepines. <i>American Journal of Drug and Alcohol Abuse</i> , 1991, 17, 457-468.	2.1	21
106	Is Buspirone Effective for Panic Disorder?. <i>Journal of Clinical Psychopharmacology</i> , 1990, 10, 3-11.	1.4	125
107	Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study. <i>Irish Journal of Psychological Medicine</i> , 1990, 7, 124-128.	1.0	5
108	A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1990, 14, 929-939.	4.8	34

#	ARTICLE	IF	CITATIONS
109	Adinazolam sustained release formulation in the treatment of generalized anxiety disorder. <i>Journal of Anxiety Disorders</i> , 1990, 4, 239-246.	3.2	8
110	Panic and Phobias: Empirical Evidence of Models and Longterm Effects of Behavioral Treatments. <i>American Journal of Psychiatry</i> , 1990, 147, 1084-1085.	7.2	15
111	An Open Study Examining the Diagnosis of Anxiety and the Use of Buspirone in a Primary Care Environment. <i>Drug Investigation</i> , 1989, 1, 3-10.	0.6	3
112	Diagnosis and Treatment of Anxiety Disorders in Children and Adolescents. <i>Psychiatric Annals</i> , 1988, 18, 146-157.	0.1	2
113	Medical Evaluation of the Anxious Patient. <i>Psychiatric Annals</i> , 1988, 18, 176-181.	0.1	3
114	Recent developments in the treatment of panic disorder. <i>Acta Psychiatrica Scandinavica</i> , 1987, 76, 75-83.	4.5	6
115	Benzodiazepines in panic disorder and agoraphobia. <i>Journal of Affective Disorders</i> , 1987, 13, 169-181.	4.1	47
116	Diagnosis and treatment of pathological anxiety. <i>Stress and Health</i> , 1987, 3, 21-32.	0.5	0
117	Panic: Facing Fears, Phobias, and Anxiety. <i>American Journal of Psychiatry</i> , 1987, 144, 1356-b-1357.	7.2	0
118	Immunological response to stress in agoraphobia and panic attacks. <i>Biological Psychiatry</i> , 1986, 21, 768-774.	1.3	40
119	Dental anxiety –the development of a measurement model. <i>Acta Psychiatrica Scandinavica</i> , 1986, 73, 559-565.	4.5	15
120	Tricyclic antidepressants in the treatment of panic and anxiety disorders. <i>Psychosomatics</i> , 1986, 27, 10-16.	2.5	33
121	A Case of Bupropion-Induced Seizure. <i>Journal of Nervous and Mental Disease</i> , 1986, 174, 496-498.	1.0	9
122	A Combination Drug Treatment for Acute Common Migraine. <i>Headache</i> , 1986, 26, 231-236.	3.9	14
123	A Three-Year Follow-Up of Hypnosis and Restricted Environmental Stimulation Therapy for Smoking. <i>International Journal of Clinical and Experimental Hypnosis</i> , 1986, 34, 169-181.	1.8	38
124	Agoraphobia: Multiple Perspectives on Theory and Treatment. <i>American Journal of Psychiatry</i> , 1985, 142, 511-511.	7.2	0
125	Monoamine Oxidase Inhibitors and Alprazolam in the Treatment of Panic Disorder and Agoraphobia. <i>Psychiatric Clinics of North America</i> , 1985, 8, 49-62.	1.3	25
126	Classification of Anxiety Disorders. , 1985, , 711-716.		3

#	ARTICLE	IF	CITATIONS
127	Panic and Other Anxiety Disorders: Diagnosis and Treatment. , 1985, , 775-781.		0
128	Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment. Journal of Clinical Psychopharmacology, 1984, 4, 66-75.	1.4	142
129	The diagnosis and drug treatment of anxiety disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1983, 7, 599-603.	4.8	9
130	The Classification of Phobic Disorders. International Journal of Psychiatry in Medicine, 1983, 12, 243-266.	1.8	78
131	Panic Attacks and Phobias. New England Journal of Medicine, 1983, 308, 341-343.	27.0	2
132	Lack of Efficacy of a New Antidepressant (Bupropion) in the Treatment of Panic Disorder with Phobias. Journal of Clinical Psychopharmacology, 1983, 3, 287-311.	1.4	68
133	Panic Attacks and Phobias. New England Journal of Medicine, 1982, 307, 156-158.	27.0	216
134	Can you recommend some literature on panic attacks and phobias that would help in their understanding and management?. Journal of Clinical Psychopharmacology, 1982, 2, 20s.	1.4	0
135	The Classification of Anxiety and Hysterical States. Part I. Historical Review and Empirical Delineation. Journal of Clinical Psychopharmacology, 1982, 2, 235-244.	1.4	47
136	Can you recommend a management strategy to guide clinicians in their implementation of the various treatment modalities for a patient with spontaneous anxiety attacks and multiple phobias?. Journal of Clinical Psychopharmacology, 1982, 2, 19s.	1.4	0
137	The Classification of Anxiety and Hysterical States. Part II. Toward a More Heuristic Classification. Journal of Clinical Psychopharmacology, 1982, 2, 386-393.	1.4	54
138	How should alprazolam be withdrawn when a patient has completed his or her trial on the drug?. Journal of Clinical Psychopharmacology, 1982, 2, 17s.	1.4	0
139	Should not panic disorders be classified as panic disorders, with or without agoraphobia, rather than agoraphobia, with or without panic attacks (as in DSM-III)?. Journal of Clinical Psychopharmacology, 1982, 2, 18s.	1.4	0
140	Age of onset of phobic disorders: A reevaluation. Comprehensive Psychiatry, 1981, 22, 544-553.	3.1	108
141	Monoamine Oxidase Inhibitors: Prescription and Patient Management. International Journal of Psychiatry in Medicine, 1981, 10, 99-121.	1.8	44
142	Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms. Archives of General Psychiatry, 1980, 37, 51.	12.3	678
143	Empirical assessment of Spiegel's hypnotic induction profile and eye-roll hypothesis. International Journal of Clinical and Experimental Hypnosis, 1979, 27, 103-110.	1.8	8
144	Influence of Psychosocial Factors on Wart Remission. American Journal of Clinical Hypnosis, 1978, 20, 160-164.	0.6	10

#	ARTICLE	IF	CITATIONS
145	Psychiatric Aspects of Oral Contraceptive Use. Psychiatric Annals, 1976, 6, 81-99.	0.1	5